Les offres proposées émanent des laboratoires du Département Scientifique Biologie-Santé ou de leurs collaborateurs en France ou à l’étranger. Vous trouverez d’autres offres sur des sites plus spécialisés:
- Le Réseau professionnel de l’Université de MONTPELLIER: ResUM
- Accès Doctorat Unique et Mutualisé: ADUM
- Écoles Doctorales Sciences chimiques et Biologiques pour la Santé: CBS2, ED 168
- Écoles Doctorales Sciences du Mouvement Humain: SMH, ED 463
- Association Bernard Gregory: ABG
Les offres sont présentées par date de publication sur le site.
We are currently inviting applications from highly motivated and autonomous postdoctoral candidates with a PhD in Immunology or Hematology to actively contribute to our ANR-funded OSTEOVALYMPH project.
Hematopoietic stem and progenitor cells (HSPCs) are responsible for replenishing immune cells and reside in bone marrow (BM) endosteal and vascular niches. The divergence of lymphoid and myeloid lineages occurs at the multipotent progenitor (MPP) stage. The influence of extracellular factors or localization of MPPs in distinct niches remains to be explored. It is also unclear whether regional BM localization of MPPs impacts their lineage specification and commitment through specific adhesion cues or chemokine signaling. In that context, we aim to decipher the molecular regulation of lymphoid-myeloid specification of MPPs with a focus on the trio formed by the chemokine CXCL12 and its receptors CXCR4 and CXCR7, among which CXCR4 has been recently involved in the deregulation of HSPC homeostasis in the WHIM Syndrome, a primary immunodeficiency. The project is coordinated by K. Balabanian and gathers three teams with complementary expertise in osteo-immunology (C. Blin-Wakkach/M. Rouleau, LP2M, Nice), leuko-stroma interaction biology (M. Aurrand-Lions/S. Mancini, CRCM, Marseille), and immunological contexture of BM niches (K. Balabanian, INSERM U1160, St-Louis Hospital, Paris).
The project will use in vivo, ex vivo and in vitro approaches to gain a better understanding of the intrinsic and extrinsic mechanisms underlying the contribution of the CXCL12 signaling axis to both localization and specification of MPPs. This is a challenging, translational proposal addressing basic scientific questions relevant for medical applications such as HSC transplantation and treatment of immune-hematological diseases. The selected candidate will be required to have a high level of skills and expertise, most importantly in animal experimentation, cellular immunology including multi-parameter flow cytometry as well as in managing human samples. The position is opened in K. Balabanian’s laboratory and will necessitate mobility to the CRCM for specific transcriptomic analyses.
To apply for this position, please contact Karl BALABANIAN.
The candidates of any nationality are expected to include a full detailed CV and a cover letter addressing their interest and motivation along with the name of at least two referees.
Expected employment starting period: September 2018
Comparative cross-country analysis of the outcomes of capacity development interventions for agricultural innovation systems
Post-doctoral Research Associate position is available at ICRA, in collaboration with CIRAD, UMR Innovation. The candidate will join our CDAIS project (Capacity Development for Agricultural Innovation Systems) whose goal is to experiment new approaches for the identification and support of capacity development of agricultural innovation systems (AIS) stakeholders in developing countries. The ultimate goal is to promote innovations to contribute to the sustainable productivity in agriculture.
CDAIS project is funded by the European Commission (EC) and jointly implemented by the European Alliance on Agricultural Knowledge for Development (Agrinatura) and the Food and Agriculture Organization of the United Nations (FAO). It started in 2015 and will end in 2019.
Applicant must have a Ph.D., M.D., or equivalent doctoral degree in a field deemed relevant to the research highlighted above.
Preference will be given to the candidate with experience in one or more of the following areas:
– Realist evaluation, change-oriented evaluation, impact evaluation;
– Database management;
– Social learning studies, organizational learning studies, behavioral studies;
– Innovation sciences, agricultural innovation system, social network analysis.
– Agricultural extension and education studies
The candidate should have excellent written and spoken English and French and working ability in Spanish. Qualified individuals will demonstrate the potential for research as evidenced by their training and peerreviewed
Please send current curriculum vitae and motivation letter before 1st March 2018 to: ICRA Montpellier office (email@example.com)
The group of Leïla Perié combines experimental and mathematical/computational approaches of lineage tracing to study hematopoiesis. In particular, the group focuses on mapping how individual cell divide and differentiate from hematopoietic stem cells to differentiated red and white blood cells. This aim at understanding key biological questions such as the effect of the environment and the dynamics of steady state hematopoiesis. In addition, the group is developing lineage tracing techniques that can be used in Human to study cell differentiation in healthy donors and cancer patients.
Starting in the second half of 2018, the successful candidate will work on using two established lineage tracing techniques (cellular barcoding and in situ barcoding). The project will be defined with the candidate and should evolve around single cell biology in hematopoiesis using new tools from the lab such as in situ lineage tracing, epigenetic and transcriptomic. Collaborations on cancer development is also be an option. The candidate should have expertize in bone-marrow transplantation, mouse experiment, multi-color facs analysis, deep sequencing. Previous experience in genetic cloning or lineage tracing will be an advantage. The candidate should be willing to work in an interdisciplinary field, in interaction with the part of the group working on theory.
How to apply
Application deadline is March 15th 2018. The interviews will take place in April in Paris. Applicants should send their detailed CV, a cover letter and contact information of two or three academic references to firstname.lastname@example.org. We strongly encourage applications from female and minority candidates.
Chromatin-mediated silencing of endogenous human retroelements
Applications are invited for an enthusiastic, motivated individual for a Wellcome Trust funded postdoctoral position in the group of Professor Paul Lehner at the Cambridge Institute of Medical Research on the Cambridge Biomedical Campus, University of Cambridge. You will join an exciting research programme using genetic and proteomic approaches to understand chromatin-mediated silencing of endogenous human retroelements, with specific reference to the novel HUSH epigenetic transcriptional repressor complex which is responsible for chromatinmediated repression of cellular transgenes and newly integrated retroviruses.
This post will involve the use of cutting edge genetic, biochemical, proteomic and bioinformatic techniques to study mechanisms of retroviral silencing. Candidates should have experience in virology or chromatin biology, in chromatin biochemistry and cell biological techniques. Quantitative and analytical skills, as well as expertise in bioinformatics are also desirable. If you have an excellent background in biological sciences, have published in high impact journals, are prepared to face intellectual challenges and wish to develop your scientific skills, we would like to hear from you. Applicants should have excellent organisation and communication skills, and work well as part of a team. Funds for this position are available for 3 years in the first instance with an immediate start date.
For further details or informal enquires please contact Paul Lehner via email (email@example.com).
Two post-doctoral positions funded by the Labex EpiGenMed and ANR are available in the group mRNA Regulation and Development at the Institute of Human Genetics in Montpellier. Our lab works on gene regulation at the mRNA level during development and diseases, in the Drosophila model. We have described the role of Piwi-interacting RNAs (piRNAs), a specific class of small non-coding RNAs, in gene regulation for several developmental processes. This function was unexpected because piRNAs were thought to be specific to the regulation of transposable elements. piRNAs and PIWI proteins are highly expressed in germ cells and stem cell lineages. In addition, piRNAs and/or PIWI proteins are ectopically expressed in cancer and neurodegenerative diseases. The post-doctoral projects concern:
1) Functions of the piRNA pathway in germline stem cells.
2) Role of the piRNA pathway and ribosomal RNAs in the genetic disease Oculopharyngeal
The Institute of Human Genetics provides a very stimulating and international research environment; it
is fully endowed with state-of-the-art scientific equipment. The Institute is located in Montpellier, an
international city in the South of France. https://www.igh.cnrs.fr.
We are looking for very motivated and ambitious candidates with strong expertise in Drosophila
genetics, imaging, metabolism, or RNA biology. Candidates should apply by sending a CV, a short outline of current projects, and contact information of two to three references to Martine Simonelig.
We are looking for very motivated and ambitious candidates with strong expertise in Drosophila
genetics, imaging, metabolism, or RNA biology.
Candidates should apply by sending a CV, a short outline of current projects, and contact information of
two to three references to:
mRNA Regulation and Development
Department Genetics and Development
Institute of Human Genetics, Montpellier, France
Marie Sklodowska-Curie Individual Fellows programme. A 2-year post-doctoral position will be applied at Marie Sklodowska-Curie Individual Fellowships in 2018 for a French scientist (post-doctoral fellow or PhD student with at least 4 years research experience). The deadline for application is September 2018.
Our research focuses on the in vivo functions of cathepsins in different pathologies. The aspartic protease cathepsin D is a poor prognostic marker of breast cancer associated with the metastatic risk. Cath-D is overexpressed by breast cancer cells and abundantly secreted in the breast tumor microenvironment. Cathepsin D stimulates breast cancer cell proliferation, fibroblast outgrowth, angiogenesis, breast tumor growth and metastasis. Whereas clinical and experimental studies established the relevance of cathepsin D in breast cancer, no animal models that provide direct evidence for the role of cathepsin D in tumor formation, progression and metastasis had yet been developed. The aim of this post-doctoral fellow is to evaluate the consequences of increased cathepsin D expression and activity on the behavior of mammary epithelial cells in a newly developed preclinical MMTV-PyMT mouse models so as to mimic the hyper-production of cathepsin D that occurs in so many human breast cancers. Novel transgenic mouse models that overproduce human wild-type cathepsin D or proteolytically-inactive D231N-cathepsin D in their mammary glands invalidated for mouse cath-D had been recently developed in collaboration between T Reinheckel’s laboratory (Institute for Molecular Medicine and Cell Research, Freiburg, Germany) and E Liaudet-Coopman’s laboratory (IRCM, Montpellier, France). These preclinical mouse models with mammary glands overproducing cathepsin D in an inducible manner will be used to study the cross-talk between epithelial and stromal cells during breast cancer progression and to validate the cathepsin D substrates recently identified. These models will also be useful for testing in vivo, the efficacy of the inhibitors of human cathepsin D that are currently being developed.
We are looking for a highly motivated candidate with good English communication skills and capacity to work independently in a collaborative
environment ((T Reinheckel’s laboratory (Institute for Molecular Medicine and Cell Research, Freiburg, Germany) and E Liaudet-Coopman’s laboratory (IRCM, Montpellier, France)). The candidate should have a strong background in cellular and molecular biology. Experience in transgenic mice is also required.
Prof. Dr. Thomas Reinheckel
Institute for Molecular Medicine and Cell Research,
Medial Faculty of the Albert Ludwigs University Freiburg
Stefan-Meier-Str. 17, 79104 Freiburg, Germany
Email : firstname.lastname@example.org
Dr E Liaudet-Coopman
IRCM, 208, rue des Apothicaires, F-34298 Montpellier Cedex 5, France
A post-doctoral position funded by the French National Agency of research (ANR) is open for a talented and highly motivated post-doc fellow to study cellular phosphate homeostasis and its misregulation leading to vascular calcification. Phosphate is an important mineral for the synthesis of membranes and nucleic acids, for energy production and signal transduction, and its concentration is tightly regulated by phosphate transporters. Little is known about how human and other metazoan cells sense phosphate to regulate phosphate homeostasis and metabolism. We are particularly interested in XPR1, a retroviral receptor that we found to mediate phosphate efflux and to be associated with a rare disease called primary familial brain calcification (PFBC). The objective of the post-doctoral project is to understand how XPR1 is integrated in this regulated sensing process and why mutations in the XPR1 gene can lead to phosphate-associated disorders like calcification. The successfull applicant will use a broad range of technics, in particular genome modifications and genetic screens, solute transport assays, as well as calcification assays in in vitro and in vivo models.
Profil: Candidates are expected to be autonomous, enthusiastic, and able to work in a collaborative team. Experience in cell and molecular biology, biochemistry and imaging is required as well as good communication skills in english. An expertise in animal studies and histology as well as a background in calcification/mineralization would be appreciated. The position is funded for 2 years and salary will be based on experience.
Applicants must hold a PhD degree in biology and should send a letter of scientific achivements and of their interest in this project, a CV with list of publications, and contact informations of 2 referees to email@example.com
A 3-year Medical Research Council UK funded position is available for a highly-motivated, ambitious candidate with strong interest in host-pathogen interaction to join the Microbial Pathogenesis research team of Dr. Gunnar Schroeder at the Centre for Experimental Medicine (CEM).
The successful candidate will drive an exciting research programme and use microbiological, cell biological and biochemical methods combined with cutting-edge imaging and proteomics analysis to elucidate new molecular mechanisms of host (macrophages/protozoa) subversion by the facultative intracellular human pathogen Legionella pneumophila, the causative agent of Legionnaires’ disease.
The Schroeder Team is based in the brand-new Wellcome-Wolfson Building providing state-of-the-art labs and research facilities. The successful candidate will be part of a dynamic and collaborative team, a vibrant, international postdoc community and have access to personal development opportunities.
The post is a senior role in the team and as such, successful applicants will have responsibilities in independent research, supervision, planning, day-to-day lab management, collaborations and outreach. The post is suited to an organised, productive and communicative individual, preferably with previous postdoctoral experience in studying the molecular mechanisms of host-pathogen interactions.
A funded two-year postdoctoral position is available in the “Nods-like receptors in infection and immunity of Lille” Unit headed by Mathias Chamaillard for studying how oscillatory behavior of the gut microbiota influence the specification fate of monocyte toward monocyte-derived macrophages or monocyte-derived dendritic cells by dictating the tolerogenic versus immunogenic intestinal microenvironment over the course of a day.
Project Outline: The International Agency for Research on Cancer classified shift work with chronodisruption as an exposure circumstance that poses a carcinogenic risk. The circadian clock is an endogenous time-tracking system that allows most living organisms to anticipate and adapt to several environmental changes. In this context, we seek to obtain a mechanistic understanding how circadian rhythm influence the continuous replenishment of the pool of intestinal macrophages by influx of monocytes from the bloodstream.
Candidate requirements: The applicants of any nationality must hold a PhD and/or a MD degree and should be highly motivated and ambitious. The applicants should have a strong background in bone marrow chimera experiments, cell cytometry and cellular imaging with a strong interest on oncology and mucosal immunology.
Interested candidates are encouraged to submit a motivation letter describing their background, a CV and two references letters to firstname.lastname@example.org.
Expected employment starting date: 2018-01-01
We are seeking highly motivated and skilled candidates with a solid expertise in mouse behavior, cell-type type specific approaches for manipulating circuit function. The appointee will test a novel hypothetical framework that could account for the impact of stress on the progression of Alzheimer’s disease neuropathology. For this, we developed a
novel conditional genetic mouse model to manipulate the neurotrophic-priming of glucocorticoid receptor signaling.
Desired skills and experience:
- Molecular biology
- Handling mouse colonies
- Behavioral assays
- Stereotactic injections
- 2-photon microscopy
From october 2018, a postdoctoral position will be available in Virginie Firlej and Francis Vacherot’s group (in the INSERM unit U955 – IMRB).
Prostate cancer is the leading male cancer in terms of incidence. In order to be able to determine the evolution of the tumor as early as the biopsy, but also to allow a better therapeutic management of the patients, it is necessary to highlight new biomarkers. From RNA sequencing data, we have been able to highlight a potential new predictive marker for aggressive cancers at risk of recurrence. The project we propose aims to evaluate this biomarker by analyzing its expression in a large cohort of patients and via the molecular study of its regulation and on the other hand by analyzing the role of this biomarker in tumor progression at the phenotypic level and its effects on the proliferation and invasion of prostate cancer cells.
The successful candidate will apply for post-doctoral fellowship from the UPEC and the ARC. In the event that the candidate has not spent more than 12 months in France in the last three years, he will have the opportunity to apply for the program PRESTIGE campus France (37000 euros per year and 4000 euros for his work)
– Recent doctoral degree in area of cancer cellular and molecular biology
– Good scientific track record (publications in international scientific journals)
– Strong experience with standard molecular and cell biology techniques. Mouse manipulation will be considered as a plus
– Capacity for autonomous work and collaborative efforts
A postdoctoral position to study the signaling mechanisms regulating epithelial stem cell fate decisions is available in the lab of Dr. Aron Jaffe in the Chemical Biology & Therapeutics Department.
The generation, maintenance, and repair of epithelial tissues require the coordinated regulation of multiple cellular processes, such as cell polarity, cell-cell and cell-matrix interactions, and
differentiation. We utilize in vivo and two- and three-dimensional culture models of epithelial morphogenesis, and employ a variety of screening and profiling methods to identify novel pathways
regulating key cellular processes involved in morphogenesis. We are particularly interested in the mechanisms regulating epithelial progenitor cell fate decisions, because an imbalance in the
differentiated cell types is observed in several pulmonary epithelial diseases, such as asthma and chronic obstructive pulmonary disease (COPD). We want to understand how epithelial progenitors
choose to differentiate down a particular lineage, and how that decision is de-regulated in disease.
The work in my lab is currently directed towards addressing three key goals:
1. Identification and characterization of the signaling pathways regulating airway basal cell fate decisions in normal and disease settings.
2. Understanding the mechanisms regulating the production and function of rare cell types in the airway.
3. Identifying the mechanisms regulating airway squamous metaplasia.
We seek highly motivated postdoctoral fellows to join our research group. The successful candidate will use cDNA and CRISPR screens, proteomics, single-cell RNA-seq, and chemical biology approaches to dissect the regulation of epithelial morphogenesis, and will capitalize on access to
multidisciplinary expertise and cross-departmental state-of-the-art resources at Novartis. Fellows will have ample opportunity and support to publish their findings in peer-reviewed, high-impact
journals. This is a unique opportunity for an independent, self-motivated candidate to enhance his/her academic training and professional horizons. The postdoctoral term is typically 4 years.
Qualifications: PhD degree in Biological Sciences • Broad knowledge and experience with cell culture, signal transduction pathways, and cellular and molecular biology techniques • Experience with
mouse models would be a plus • Excellent analytical and communication skills and a strong motivation to independently ask and test scientific hypotheses are crucial.
Qualified candidates should apply through http://postdoc.nibr.com/aron-jaffe.html and also by directly contacting Dr. Aron Jaffe.
Position: Postdoctoral position in onco-immunology
Required diploma: Ph .D.
Project: In our team, we are developing new therapeutic alternatives to counter cancer resistance to therapies proposed in the clinic. The present project aims to study the molecular mechanisms involved in the anti-tumor immune response of an anti-cancer agent against breast cancers, as well as its association or comparison with other therapeutic agents. These studies will be conducted in vitro and in vivo. This project is based on works of the team already very advanced that showed the impact of this agent on the immune system and on the tumor and revealed very original mechanisms, placing this agent as very innovative compared to the immunotherapies tested in the clinic.
Main mission: To complete the study of the efficacy of an anti-cancer agent, developed in the team, against breast cancers and to identify the mechanisms of action, involving the immune system, in its anti-tumor response.
Main activities: The candidate will have to use all the classical techniques of immunology, cell biology and molecular biology used in laboratories (cell culture, cell transfection, flow cytometry analysis, western blot, qPCR etc). It will manipulate animals (tumor grafts, treatments, organ and tumors harvesting etc.) and to analyze samples by these different techniques, immune cell populations, cytokine levels etc.). He will have to use transgenic animals and chimeras on the immune system or on certain genes. He will have to plan the experiments to be carried out, to realize them, to analyze them and to format the data, and to present the data to the supervisors and to the laboratory.
Associated activities: Participate in team life, scientific discussions and meetings, order management, laboratory logistics.
Job constraints: According to the experiments, the candidate will have to work in specific experimental zone.
Main skills required: In-depth skills and autonomy in the field of immunology is required, PhD in immunology desired. In-depth knowledge of the subpopulations of immune cells (dendritic cells and T lymphocytes in particular, macrophages would be a plus). Competence in animal experimentation requested. Know-how in the creation of chimeric animals on the immune system is desired.
Other skills: Being dynamic, organized, rigorous, like to learn and share.
Salary: Gross monthly remuneration from € 2544.51, and more according to experience.
Position to be held: January-February 2018.
Some publications of the team:
1- de Medina et al, PNAS, 2010
2- de Medina et al, Nat commun, 2013
3- Silvente-Poirot et al, Science, 2014
4- Silvente-Poirot et al, Biochimie, 2016
5- Poirot et al, Biochem Soc Trans. 2016
6- Leignadier J et al, Biochem Pharmacol, 2017
7- Dalenc et al, J Steroid Biochem Mol Biol, 2017
8- Voisin et al, PNAS, 2017
9- Segala et al, Nat commun, in press
Contact : Please send your application with CV, letter of motivation, letters of recommendation to Sandrine Silvente-Poirot.
A post-doctoral position is available in Sophie Postel-Vinay’s ATIP-Avenir group at U981 INSERM as of February 2018 to work on therapeutic approaches to target chromatin
remodeling deficiencies in solid tumors.
Recent large scale tumor genomic profiling studies have uncovered mutations in several chromatin remodeling genes, notably SWI/SNF (Switch / Sucrose Non-Fermentable) subunits,
in approximately 20% of all solid tumors, highlighting its pivotal role in tumorigenesis and making it a potential target for cancer therapy. While chromatin remodeling deficiency has
been extensively studied in tumorigenesis, little is known about how to selectively target defects in the SWI/SNF-chromatin remodeling complex, and no targeted drug is approved to
date in such indication.
The INSERM/CNRS-funded research programme will focus on identifying novel therapeutic approaches for targeting SWI/SNF deficiency, using hypothesis-based and hypothesis-
generating approaches. The selected post-doctorant will be involved in identification and the molecular dissection of genetic vulnerabilities of chromatin-remodeling deficient tumors. The
programme will be developed at the basic research and fundamental level, as well as at the translational level thanks to a direct collaboration with the Drug Development Department of
Gustave Roussy’s Hospital. If relevant, results of the program could lead to clinical applications at Gustave Roussy. The INSERM U981 Unit is fully equipped to allow the development of such
program, both for preclinical and in vivo studies.
Keywords: cancer, solid tumors, chromatin remodeling, targeted therapy, genetic vulnerability.
– Strong scientific track record (international publications and communications)
– Robust experience with molecular and cell biology techniques; experience in the study of chromatin biology and transcriptional or epigenetic dysregulation; bioinformatics notions will
be of added-value
– Ability of collaborative team work and autonomous work
– High motivation
– Fluency in English
– Curriculum vitae (including list of publications and communications)
– Motivation letter describing previous experiences and reasons underlying the application
– Contact information for referees or previous mentors
Applications should be sent to Dr Sophie Postel-Vinay
A 2-year post-doctoral position, starting on April 1 st 2018, is available in the team “Cancer Cell Signaling and Therapeutics” headed by Gilles Favre at the Cancer Research Center of Toulouse
(CRCT) in Toulouse. This position is offered in the context of the FRM “labellisation” of the team.
Description – Our research focuses on the mechanisms of acquired resistance to targeted therapy, primarily in lung cancer. A recent mechanism of resistance implies the survival of few
tumor cells to treatment, which arrest their proliferation, and acquire over time validated genetic resistance to therapy allowing the tumor to regrowth. The post-doctoral candidate will
primarily investigate how non-cycling cells acquire those genetic resistances on the basis of our findings that DNA double-strand breaks, which are highly mutagenic, are produced in non-
cycling cells when an ongoing transcription complex encounters a topoisomerase I lesion onto chromatin (NAR 2016; MCB 2014; EMBO Rep 2009). This project will include techniques such as
ChIP-seq, whole-exome-seq and high content imaging system (Operetta).
The selected candidate will perform his (her) research in the highly stimulating environment of the Cancer Research Center of Toulouse (CRCT), which is located in a campus dedicated to cancer bringing together
academic research, private companies and a hospital. He (she) will benefit of all the cutting-edge technology platforms of the center.
Applicant profile – We are looking for a highly motivated and enthusiastic applicant with a PhD and a strong background in cellular and molecular biology. Experience in ChIP and genome-wide
analyses is preferred but not required. This grant is for funding a first post-doctoral position after a PhD.
Contact – This project will be supervised by Olivier Sordet, a senior scientist in the team. To apply, please reply to Olivier Sordet with a CV including list of publications, a short
description of research interests, and 2 recommendation letters.
Starting date: April 1 st 2018
Duration: 2 years
Gross salary: 2,544 euros/month
The group of Pierre Roux at CRBM is offering a 3-year postdoctoral fellowship position funded by INCa, starting early 2018.
Our project is focused on the p53 tumor suppressor gene, the most frequently mutated gene in all cancer types. The p53 gene produces a complex profile of alternatively spliced transcripts and can generate at least twelve protein isoforms. The team recently showed that the Δ133p53ß isoform constitutes a biomarker of shorter disease-free survival for patients suffering from breast or rectal cancer. This isoform controls cancer stem cell potential, cell invasion, EMT and metastasis. These properties are independent of p53 mutation status. For more information on the Team, visit our web page. The candidate will be involved in two main objectives: unravel the signaling that produces Δ133p53ß and identify the mechanisms by which this isoform exerts is pro-invasive activity.
• We welcome applications from scientists in cell biology and cancer biology.
• The candidate has a PhD in cancer biology (with or without post-doc experience). He/she must have expertise in high-throughput RNA sequencing data and experience in standard molecular and cell biology technique. The candidate should also have an excellent track record of publications.
• We are searching for a postdoc fellow who can work independently and develop his/her own ideas and visions in line with the project. Candidates should be highly motivated, creative, and have strong communication skills. The ability to communicate in English at a high level, interact effectively and work productively in a team will be considered important.
How to Apply:
Please send application package to Pierre Roux, including:
• a cover letter briefly stating your previous research experience, why your skills would suit the job and your reasons for applying
• a CV including your publication list
• two or more reference letters or contact details.
The group of Dr. Cédric Delevoye within the team headed by Dr. Graça Raposo is located at the Institut Curie, center of Paris, France. We are studying the cellular and molecular mechanisms that control human skin pigmentation in health and disease. We focus on the trafﬁcking events leading to the biogenesis, maturation and homeostasis of the pigment granule of epidermal melanocytes, called the melanosome. Within the ANR MyoActions, we propose a multi-scale analysis (from structure to chemistry and cell biology) to provide insights into how molecular motors, associated partners and the forces they produce can remodel membrane of organelles. Our work integrates cell biology, biochemistry and advanced cellular imaging (EM, CLEM) to deﬁne the generation of transport intermediates required for pigmentation.
Applicants should have a strong interest in the mechanisms of intracellular trafﬁcking and wish to work in a multidisciplinary environment. We are seeking for a creative and self-motivated Post doctoral fellow with research experience in the ﬁeld of Cell Biology.
Expertise in microscopy and/ or genome editing will be a plus. English (written/oral) is required.
Applicants should send their CV along with a cover letter and contact details of three references to Cédric Delevoye (deadline end of 2017).
Keywords: Organelle, Membrane Remodelling, Myosin, Skin Pigmentation, Intracellular Trafﬁcking, Imaging
1.Patwardhan A, et al. Routing of the RAB6 secretory pathway towards the lysosome related organelle of melanocytes. (2017). Nat Commun. 8:15835.
2.Dennis MK, Delevoye C et al. BLOC-1 and BLOC-3 regulate VAMP7 cycling to and from melanosomes via distinct tubular transport carriers. (2016). The Journal of Cell Biology. 214(3):293.
3.Delevoye C, et al. BLOC-1 Brings Together the Actin and Microtubule Cytoskeletons to Generate Recycling Endosomes. (2016). Curr Biol. 26(1):1.
4.Delevoye C, et al. Recycling endosome tubule morphogenesis from sorting endosomes requires the kinesin motor KIF13A. (2014). Cell Rep. 6(3):445.
5.Loubery S, Delevoye C et al. Myosin VI regulates actin dynamics and melanosome biogenesis. (2012). Trafﬁc. 13(5):665.
The Laboratory of Regulation of Gene Expression at the Institute of Microbiology CAS in Prague led by Dr. Leos S. Valášek is seeking to fill a Postdoctoral fellow position in the area of regulation of Translational control in humans. One of the main goals of the Valasek laboratory’s research program is to understand the role of several eukaryotic initiation factors in the process of regulation of translation initiation and termination in humans in both general, as well as gene-specific manner. The successful applicant will develop a new research project aiming to describe novel echanisms of translational control in human cells and their deregulation in cancer cells using state-of-the-art molecular studies.
Qualifications and experience:
You must have:
– a PhD degree or its equivalent awarded no more than 7 years ago. The 7 years period may be extended for the maternity and paternity leave period, long-term sickness (more than 90 days), care for a family member (more than 90 days), pre-attestation preparation and military training;
– at least 5-years long experience working in the field of regulation of gene expression and a broad knowledge of the principles of molecular biology (qPCR, cloning, immunoprecipitation, western blotting), genetics and biochemistry, as well as modern methodological approaches in higher eukaryotes;
– expertise in ribosomal profiling/footprinting, high throughput sequencing like RNA seq and its data analysis using various bioinformatic and biostatistical approaches would be very valuable;
– a proven ability to lead students and younger colleague-researches;
– a commitment to drive scientific projects, motivation for high impact, high quality research, ability to work closely with an interdisciplinary research team;
– a solid record of peer-reviewed publications;
– an excellent writing and communication skills in English – international certificate (min. B2 or its equivalent).
You must be:
– either a researcher who has worked for at least 2 years over the period of the last 3 years in an organization/organizations outside the Czech Republic with the working time of at least 0.5 FTE, or a former Ph.D. student who studied abroad and completed his PhD studies no later than a year ago. Both categories include Czech citizens.
We offer the work in dynamic and multidisciplinary environment of the closely cooperating international team of the Laboratory of Regulation of Gene Expression of the Institute of Microbiology in Prague. The laboratory is supported by the Wellcome Trust, as well as by the Centre of Excellence Grant awarded by the Czech Grant Agency. Gross salary: 2900 USD / month, 30 days paid holiday per year. The starting date is negotiable, but the position has to start before April 30, 2018. The position is offered for two years and is supported from the European Union Funds – Operational Programme Research, Development and Education.
Please email your professional Curriculum Vitae (including the list of your publications), a motivation letter, copies of relevant course/degree certificates, and at least two letters of reference from independent senior researchers, such as your previous supervisor(s) or lead scientist(s).
Subject of the e-mail: postdoc – gene expression
Closing date: December 31th, 2017
About the employer:
The Institute of Microbiology of the Czech Academy of Sciences in Prague, Czech Republic http://mbucas.cz/en/ represents the leading and largest institution (over 500 employees) of basic research in microbiology in Central and Eastern Europe, with a track record of scientific excellence in research on microbial secondary metabolism, microbial cell biology, photosynthetic microorganisms, immunology and molecular and cellular biology of microbe interactions with environment.
You can also visit us at http://www.biomed.cas.cz/mbu/lrge/.
Project: Metabolism of Foxp3 regulatory T cells in mice
The postdoctoral fellow will work on a project entitled: “Role and characterization of cellular metabolism on Treg biology at steady state and during inflammation”. Foxp3 regulatory T cells (Tregs) play a critical role in the control of autoimmune and chronic inflammatory diseases and in the suppression of anti-tumor immunity. It is well known that cellular metabolism has a strong impact on biology of conventional T cells but few is known for Tregs. To address the role of cellular metabolism on Treg biology and function, we have generated mice that have a conditional knockout for mTOR, AMPK, LKB1, ICOS and leptin receptor in Tregs. The postdoc will use these mice to study the role of homeostatic and inflammatory factors of various tissues on Treg biology and metabolism in context of spontaneous or induced autoimmunity, chronic inflammation and cancer.
• Activities: The postdoc will design and set up experiments as required for the progression of the project. The immune system of mice that develop spontaneous autoimmunity will be studied by flow and mass cytometry, Treg culture and transcriptomic analyses. Metabolic activity of Tregs will be studied by mass spectrometric metobolomics and Seahorse analyses. In vivo biologic parameters of Tregs (migration, survival, proliferation and stability) will be analyzed by adoptive transfer and by using fate-mapping mice.
• Knowledge: Previous experience in immunology is required as well as expertise in mouse manipulation, multiparametric flow cytometry and cell culture. Basic knowledge in bio-informatics would be an advantage.
• Professional skills: The candidate must be highly motivated and use creative thinking in the resolution of scientific questions. He/she will be able to adapt to rapidly evolving technologies and will have a broad interest for biomedical research. He/she will need to give proof of independent thinking and writing skills and capacity to undertake responsibility as project leader. It is essential that the candidate can work autonomously and as part of a team.
• Education: MD/PhD or PhD in biological sciences.
The work will be performed in the Treg Biology and Therapy team that is part of the Cimi-Paris Institute in the center of Paris. The team has been working on Tregs for many years. We showed that Tregs play a major role in the control of autoimmunity (Immunity 2000, J Immunol 2016), GVHD (J Exp Med 2002, J Clin Invest 2003) and atherosclerosis (Nat Med 2006), that they are not anergic in vivo (J Exp Med 2003), that low dose IL-2 administration boost Tregs and suppress type 1 diabetes (Immunity 2008 and J Exp Med 2010), that Teff have paradoxical protective effects in type 1 diabetes by boosting Treg via TNF (J Clin Invest 2010, J Immunol 2015) and that TNF does not inhibit function of human Treg (Nat Med 2016). More recently, we have developed multiple conditional KO mice to study cellular metabolism in Treg biology. Our research has led to clinical trials in GVHD and autoimmune diseases. BS has published important findings as first or last author. Among them, 8 have more than 50 citations (6 over 350 and 1 over 1850 citations).
We offer a stimulating and productive lab environment of young researchers with strong team spirit. This is an excellent career opportunity, as the candidate will have a senior role within the laboratory and interact with several international collaborators.
For further information about our Institute: http://www.cimi-paris.upmc.fr/en/index.html.
Financial support :
Type: Temporary position Funding: Agence Nationale de la Recherche (ANR).
Starting date: From January to June 2018.
Duration of contract: 3 years.
How to apply:
Applicants should send their CV, list of publications, a summary of previous research experience and the names of two references to Benoit Salomon.
Main publications of the team:
• Burlion A et al. Targeting the Human T-Cell Inducible COStimulator Molecule with a Monoclonal Antibody Prevents Graft-vs-Host Disease and Preserves Graft vs Leukemia in a Xenograft Murine Model. Front. Immunol. 2017. 8:756.
• Zaragoza et al. Suppressive activity of human Treg cells is maintained in the presence of TNF. Nat Med 2016. 22:16.
• Baeyens et al Effector T cells boost regulatory T cell expansion by IL-2, TNF, OX40 and plasmacytoid dendritic cells depending on the immune context. J Immunol. 2015. 194:999.
• Petit et al. Gene transfer of two entry inhibitors protects CD4+ T cell from HIV-1 infection in humanized mice. Gene Ther. 2016. 23: 144–50.
• Goldstein JD et al. Inhibition of the JAK/STAT Signaling Pathway in Regulatory T Cells Reveals a Very Dynamic Regulation of Foxp3 Expression. PLoS One. 2016. 11:e0153682.
• Grégoire et al. Treatment of Uveitis by In Situ Administration of Ex Vivo-Activated Polyclonal Regulatory T Cells. J Immunol. 2016. 196:2109.
• Grinberg-Bleyer et al. Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs. J Clin Invest. 2010. 120:4558.
• Grinberg-Bleyer et al. IL-2 reverses established type one diabetes by a local effect on pancreatic regulatory T cells. J Exp Med. 2010. 207:1871
A postdoctoral position is available in the laboratory of Alberto Ciccia in the Department of Genetics and Development at Columbia University Medical Center. The Ciccia laboratory is located in the state-of-the-art Irving Cancer Research Center. The Ciccia laboratory studies the cellular pathways that maintain genomic stability to prevent the development of breast and ovarian cancer (Taglialatela et al, Molecular Cell, 2017). Furthermore, the Ciccia laboratory investigates the mechanisms of CRISPR-mediated gene editing and develops novel CRISPR-dependent technologies (Billon et al, Molecular Cell, 2017; http://www.ciccialab-database.com/istop). Information about current projects of the Ciccia laboratory can be found at https://www.ciccialab.com/.
Interested candidates with Ph.D., M.D. or equivalent degrees are encouraged to apply. Experience in molecular and cell biology, protein biochemistry, mouse genetics or computation biology and first-authored publications in peer-reviewed journals are preferred.
To apply for this position please submit a cover letter describing research experience and interests, CV and contact information of three references to:
Department of Genetics and Development
Irving Cancer Research Center
Columbia University Medical Center
1130 St. Nicholas Avenue
New York, NY 10032
POST-DOCTORAL POSITION – Use of chemical tools to probe DNA and histone methylation
We are looking for a talented and curiosity-driven post-doc interested at the interface of chemistry and biology to join us in our new laboratory at the Institut Pasteur. Epigenetic modifications act together with transcription factors and other proteins to establish the expression profiles that are inherited from cell to cell, integrating various environmental stimuli. In cancers, alterations of the epigenetic landscape have been observed, but also in other pathologies. We have developed and characterized in cancer cells inhibitors of DNA methylation (reviews: Pechalrieu et al. Biochem Pharmacol. 2017;129:1-13; Lopez et al. Adv Exp Med Biol. 2016; 945:431-473; Erdmann et al. J Med Chem. 2015 58(6):2569-83), an epigenetic mark altered in cancers. We have recently started to apply our approaches to histone methylation (Castillo-Aguilera et al. Biomolecules. 2017 Jan 5;7(1). pii: E3).
With our arrival at the Institut Pasteur we propose to implement the use of these chemical scalpels to dissect the complex cellular events that control the DNA and histone methylation profiles in cancer and in other pathologies. The successful candidate will join a team of chemists and biologists working together in synergy. She/he will manage two projects:
-the development of robust assays, in vitro and/or in cells, to screen an oriented chemical library designed and synthetized in house. A crosstalk with the chemists of the team is essential to the project;
-the use of the compounds as chemical tools to identify the molecular mechanism in the cells by chemical pulldown and “omic” analysis and by molecular and cellular biology techniques to follow the consequences of the drug treatments.
The candidate should have skills in enzymology, biochemistry, molecular and cellular biology. The candidate should be very open to cooperation with the other members of the lab and to collaborations with external partners.
The post-doctoral position at the Institut Pasteur, Paris, is for 12 months, renewable.
Starting dates are flexible, with a preference for beginning of April 2018.
Application, including a CV, two reference letters and detailed contacts, should be sent by email to Paola Arimondo.
Closing date: January, 5th 2018
Description of the project
Cellular mRNAs are subjected to a balance between synthesis and degradation, which determines the shape of the transcriptome and greatly participates to protein homeostasis. In addition to the general degradation pathways, which ensure the turnover of each mRNA, a number of quality control mechanisms target aberrant RNAs for degradation. mRNA turnover has been shown to occur co-translationally, mainly by the Xrn1-dependent 5’ to 3’ degradation pathway. It also involves, although to a lesser extent, the exosome/SKIdependent 3’ to 5’ pathway. We recently showed that the SKI complex directly interacts with ribosomes and that this interaction takes place during the general 3’ to 5’ mRNA degradation pathway. This seems paradoxical because the SKI complex was previously shown to be required for the efficient degradation of mRNA 3’UTRs, mainly devoid of ribosomes. Recently, we characterized, in Saccharomyces cerevisiae, a new complex involved in the degradation of the ribosomes-free RNA 3’UTRs and cytoplasmic lncRNAs such as XUTs and SUTs. We propose a model to describe the role of this complex. The main aim of this project is to test our working model using genetics, biochemical, functional and structural approaches. The structural approach will be performed in collaboration with the Roland Beckmann team, in Munich, specialized in the cryo-EM structure determination.
Characterization of a new complex involved in the degradation of cytoplasmic transcripts
Location: Institut Pasteur, Paris
Laboratory: Génétique des Interactions Macromoléculaires
Application for two years funded by ANR
Description of the project:
Cellular mRNAs are subjected to a balance between synthesis and degradation, which determines the shape of the transcriptome and greatly participates to protein homeostasis. In addition to the general degradation pathways, which ensure the turnover of each mRNA, a number of quality control mechanisms target aberrant RNAs for degradation. mRNA turnover has been shown to occur co-translationally, mainly by the Xrn1-dependent 5’ to 3’ degradation pathway. It also involves, although to a lesser extent, the exosome/SKI-dependent 3’ to 5’ pathway. We recently showed that the SKI complex directly interacts with ribosomes and that this interaction takes place during the general 3’ to 5’ mRNA degradation pathway. This seems paradoxical because the SKI complex was previously shown to be required for the efficient degradation of mRNA 3’UTRs, mainly devoid of ribosomes. Recently, we characterized, in Saccharomyces cerevisiae, a new complex involved in the degradation of the ribosomes-free RNA 3’UTRs and cytoplasmic lncRNAs such as XUTs and SUTs. We propose a model to describe the role of this complex. The main aim of this project is to test our working model using genetics, biochemical, functional and structural approaches. The structural approach will be performed in collaboration with the Roland Beckmann team, in Munich,specialized in the cryo-EM structure determination.
Qualifications and experiences:
Candidates should have a PhD degree in Life Sciences. He/She must have a good knowledge of molecular biology, genetics and biochemistry. Experience with yeast and bioinformatics skills would be an asset. High motivation and a good ability to work independently as well as within a team environment are required.
If you are interested in this position, please send your CV and a letter of motivation to Micheline Fromont-Racine. This position is funded by the ANR and could start the 1 st of January, 2018.
Intitulé du Poste : Chercheur postdoctoral en biotechnologie
Salaire : selon profil
Présentation de l’entreprise : Cellvax est une entreprise prestataire des services innovants permettant d’accélérer le développement de médicaments. Constituée d’une équipe de scientifiques et d’experts en biotechnologie, Cellvax met son savoir-faire et sa capacité d’innovation à la disposition des laboratoires publics et privés, engagés notamment dans la recherche contre le cancer et l’arthrose.
Fonction ou mission : Suite à un accroissement d’activité, Cellvax recrute des chercheurs post-doc en Biotechnologie, capables de réaliser des études précliniques (BPL et non BPL). Sous la responsabilité du Directeur d’Etude, les tâches à effectuer sont:
• Réaliser des études en conditions BPL : mise en œuvre, rédaction des procédures, réalisation des expérimentations (in vitro et in vivo), enregistrement des données, analyses statistiques, rédaction de rapports d’étude;
• Développer des modèles d’étude in vivo et in vitro dans divers domaines (oncologie, arthrose, ophtalmologie);
• Contribuer à l’agencement de l’installation avec noter Consultant Qualité, pour la mise en conformité BPL du laboratoire;
• Contribuer à la gestion du stockage, la conservation des archives et matériaux, la traçabilité
• Veille scientifique et réglementaire.
– Compétences en techniques de biologie moléculaire (extraction d’acides nucléiques, RT, qPCR…), biologie cellulaire (culture primaire et lignées, analyse…), biochimie (WB, ELISA, ELISA…), expérimentation animale;
– Expérience exigée en expérimentation animale (certificat Niveau I ou II) – Maîtrise des techniques d’injection, prélèvement d’organes, chirurgie (microchirurgie est un plus);
– Connaissance de l’environnement règlementaire BPL;
– Expérience en gestion de projets;
– Qualités personnelles : autonome, rigoureux, aisance relationnelle;
– Maitrise de l’anglais.
-1/2- Conditions restrictives sur les candidatures
Obligatoire : Certificat en expérimentation animale.
Déplacements à l’étranger.
Nature du contrat : CDD, possibilité CDI en cas de la réussite de la mission
Modalités de dépôt de candidature et contact : Envoyer vos dossiers complets (CV, lettre de motivation, lettre de recommandation) à : email@example.com
Lieu de travail principal
Cellvax, SAS. Parc Biocitech ; 102, Avenue Gaston Roussel
93230 Romainville France Site Web : www.cellvax-pharma.com
Mots clés : cancer, arthrose, culture cellulaire, PCR, modèles animaux, immunothérapies
A 33 months post-doctoral position funded by the European H2020 grant agency is open for a talented and highly motivated post-doc fellow to join a research group to contribute to the study and evaluation of circulating DNA analysis.
Circulating cell-free DNA (cfDNA) is a potential source of tumor material available with a simple blood sampling enabling a non-invasive quantitative and qualitative analysis of the tumour genome. CfDNA analysis has a great potential especially for cancer screening, prognosis and monitoring of the efficacy of anticancer therapies. Dr. Thierry’s team is pioneering in clinically implementing cfDNA analysis by demonstrating its clinical validation as well as its clinical utility, and now co-organized ongoing and future several clinical assays on the evaluation of this diagnostic approach to detect the minimal residual disease, to monitor treatment and the surveillance of the recurrence as well as screening test. The successful applicant will have various responsibilities in researching new analytical methodologies, designing study models, performing analysis, data recording, and participating to the organization of the team work within the European LIMA project.
- Thierry AR, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat. Med. 2014 Apr;20(4):430-5.
- Thierry AR et al, Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment. Annals Oncol. 2017 Sep 1;28(9):2149-2159.
- Thierry AR et al Circulating DNA demonstrates convergent evolution and common resistance mechanisms during treatment of colorectal cancer. Clin. Cancer Res., 2017 Aug 15;23(16):4578-4591.
Context: The candidate will be part of the LIMA project aiming at evaluating cfDNA diagnostic potential in the course of the management of locally advanced cancer (Breast and rectal cancer). The team “Integrated Research for the Personalized Medicine in Digestive Oncology” within the Institute of Research on Cancerology of Montpellier provides a unique training environment for both discovery-based and translational therapeutic oncology research combining medical doctors and researchers from both fundamental and clinical fields. In addition, this will be enlarged through the close collaborative works with the other European partners from UK, Netherlands, and Germany.
Requirements: The ideal candidate should hold a PhD or MD with a strong background with molecular biology. Individuals with additional working knowledge in Q-PCR or DNA sequencing are strongly encouraged to apply. Good knowledge of English, interpersonal and communication skills are also required.
Please send a CV, names and contact information of three references and a short description of your scientific interests by email to Dr. A.R. Thierry
L’UMI233 TRANSVIHMI de l’Institut de Recherche et Développement (IRD) est une unité de recherche multidisciplinaire qui est aussi affiliée à l’Inserm (U1175) et l’université de Montpellier. Elle mène des études sur les caractéristiques cliniques et virologiques du VIH mais aussi sur les aspects programmatiques et socio-culturels dans les pays à haute prévalence d’infection VIH et ressources limitées, notamment en Afrique. Cela inclut aussi les autres maladies associées au VIH comme la tuberculose.
L’UMI233 est associée à un projet financé par UNITAID et dirigé par la fondation « Elizabeth Glaser Paediatric AIDS Foundation » (EGPAF): CAP TB (Catalyzing paediatric TB innovation). Ce projet vise à réduire la morbidité et mortalité de la tuberculose de l’enfant en augmentant l’accès au traitement. L’UMI233 va évaluer une approche de dépistage et prophylaxie antituberculeuse des enfants contacts d’adultes malades de la tuberculose au sein de la communauté en comparaison avec une approche au sein des services de santé. Un essai randomisé en cluster sera conduit au Kenya, Cameroun et Ouganda.
Missions: Développer, mettre en place et coordonner un essai clinique sur la tuberculose dans trois pays africains :
Ouganda, Kenya et Cameroun.
The Max F. Perutz Laboratories (MFPL) at the Vienna Biocenter Campus have an open call for tenure-track Junior Group Leader positions. (http://www.mfpl.ac.at/about-us/open-positions/position/news-detail/faculty-openings.html)
We are recruiting outstanding scientists from any research field that addresses fundamental biological questions. MFPL is also interested in recruiting scientists, who work at the interface of medicine and biology.
Post-doctoral position: “Overcoming resistance to ibrutinib”
We propose a post-doctoral position for one and a half year in our team located in Lyon Sud campus.
Project: B cell lymphomas are a heterogeneous group of cancers arising from B lymphocytes. Most of them are dependent on the signals from their antigen receptor (B cell receptor, BCR) for their survival and proliferation. Hence, inhibitors of the signaling pathways downstream the BCR have been developed, such as ibrutinib, the first inhibitor of the Bruton Tyrosine kinase (BTK). Despite impressive response rates, relapses occur driven by ibrutinib resistant clones carrying the C481S mutation of BTK. The outcome of patients harboring this mutation is very poor.
This work explores two strategies to overcome ibrutinib resistance:
Collateral sensitivity The concept of collateral sensitivity means that a mutation of a kinase conferring resistance to an inhibitor might create an unexpected sensitivity to another inhibitor. This concept has been validated with axitinib in T315I mutated BCR-ABL. We have established a cell line whose survival is strictly dependent on BTK or BTK-C481S. This cell line has already been use in a screen of all the FDA-approved chemical compounds (Prestwick library) and is now used in a screen of kinase inhibitors. We have also established genetically modified lymphoma cell lines for validations of interesting hits.
Non-oncogenic addiction To survive to the stress created by the activation of oncogenes, cancer cells rely on stress pathways that might be therapeutically targeted. The objective of this project is to determine what are the non-oncogenic addictions created by the activation of the BCR pathway, with a whole genome CRISPR/Cas9 screen in a lymphoma cell line with or without overactivation of the BCR. Our first attempts to activate the BCR pathway with a constitutively activated mutation of BTK were not conclusive, and this model needs to be improved. The use of whole genome CRISPR/Cas9 screen is already ongoing in the team for other projects.
The Team The team “Clinical and experimental models of lymphomagenesis”, headed by Laurent Genestier and Gilles Salles, belongs to the Centre de Recherche en Cancérologie de Lyon (CRCL). This teams comprises full time researchers and medical doctors, as well as post-doctoral researchers, doctorants and ingeneers, and develop in vitro and in vivo models of lymphomas to understand lymphomagenesis and develop therapies.
B cell lymphomas are a heterogeneous group of cancers arising from B lymphocytes. Most of them are dependent on the signals from their antigen receptor (B cell receptor, BCR) for their survival and proliferation. Hence, inhibitors of the signaling pathways downstream the BCR have been developed, such as ibrutinib, the first inhibitor of the Bruton Tyrosine kinase (BTK). Despite impressive response rates, relapses occur driven by ibrutinib resistant clones carrying the C481S mutation of BTK. The outcome of patients harboring this mutation is very poor.
The team “Clinical and experimental models of lymphomagenesis”, headed by Laurent Genestier and Gilles Salles, belongs to the Centre de Recherche en Cancérologie de Lyon (CRCL). This teams comprises full time researchers and medical doctors, as well as post-doctoral researchers, doctorants and ingeneers, and develop in vitro and in vivo models of lymphomas to understand lymphomagenesis and develop therapies.
Contact : firstname.lastname@example.org
tel 06 64 77 59 12
Assistant Professor in Neurosciences-Neuro-oncology at the Normandie Rouen University
The University of Rouen Normandie nurtures internationally strong social and economic links in the fields of energies, aeronautics, logistics, transports and mobility, cosmetology and
health. It plays a major role in terms of innovation, through learning institutes, clusters and competitive hubs. The Institute for Research and Innovation in Biomedicine (IRIB –
FED4220) is a Federative Structure of Research regrouping all the resources of biomedical research in Haute-Normandie with the objective to develop a high-level biomedical research
particularly focused on the understanding of disease physiopathology and the development of new diagnostic and therapeutic tools thanks to the complementarities of clinicians, biologists
and chemists of the Normandie Rouen University.
Tenure track as Assistant Professor in Neurosciences- Neuro-oncology
Required basic qualifications:
Candidates must have a PhD or equivalent degree at the time of application. French candidates must be qualified in one of the following sections: 65, Biologie cellulaire; 66, Physiologie; 69, Neurosciences.
The candidate will join the team Astrocyte and Vascular Niche within the UMR1239 INSERM, DC2N, Rouen. The general objective of the project is to tackle the glial tumor-brain interface in an original angle by developing molecular and cellular approaches and animal models, particularly by means of electrophysiological and in vivo brain imaging. The candidate must possess a solid expertise in neurophysiology, cell signaling with skills in electrophysiological techniques and/or dynamic imaging in vivo. The mastery of molecular tools to target brain/tumor cell populations will be a plus. The candidate will have free access to the local platforms and services of imaging, proteomic, genomic of IRIB federation, to the expertise of the team and of the platform Cancer and Cognition, and will benefit from the infrastructures available in the central animal facility of the UFR Sciences and Techniques.
The Assistant professor will teach in the field of Neurosciences and Animal Physiology, including electrophysiology and cellular and molecular neurobiology. She or he will be involved in teaching and mentoring neurosciences and physiology skills, participate to international education and exchanges with foreign researchers involved in international training, and be associated with the development of innovative teaching tools (Tice, e-Learning, etc.) and continuing education. The courses concerned are the « Life Sciences », in particular « Biochemistry, Molecular Biology, Cellular and Physiology », « Sciences for Health » and the Master « Neurosciences » in the « Neuroscience molecular, cellular and integrated » course. Involvement is expected in international thematic schools and new translational training streams.Host Team: The candidate will develop his work in the laboratory of Neuronal and Neuroendocrine Cell Communication and Differentiation (Inserm U1239, Dir. Y. Anouar) whose research is focused on cerebral and neuroendocrine pathologies. The candidate will integrate the « Astrocyte and Vascular Niche » team (Dr. H Castel), whose work focuses on the cellular and pathophysiological mechanisms that control brain tumorigenesis (proliferation, migration, invasion, angiogenesis, resistance to treatment) and impact of cancer and/or cancer
therapies on the functions of the central nervous system. The general objective of the team is to understand the determinants of the invasion of the cerebral parenchyma by glial tumor cells
and to seek new therapeutic approaches by combining cellular and animal models up to clinical studies.
Contact: Dr Hélène Castel, DR2 Inserm
Tel : 33-2-35-14-66-30
Université de Rouen Normandie
Role of Pluripotency-Associated Proteins in Genomic Imprinting
This post-doctoral researcher position in epigenetics is at the Institute of Molecular Genetics (IGMM; http://www.igmm.cnrs.fr ) in Montpellier, France, and concerns the regulation of
genomic imprinting in mammals.
Imprinted genes play essential roles in development and disease. Their mono-allelic expression is regulated by differentially-methylated ‘imprinting control regions’ (ICRs). The allele-specific DNA methylation imprints at these ICRs are stably maintenance throughout development. It remains unknown, however, how the unmethylated alleles of ICRs are maintained and what protects these against de novo DNA methylation in the early embryo.
This post-doctoral project explores the role of different pluripotency-associated proteins that are expressed in embryonic stem and primordial germ cells. The goal of the research is to unravel the characteristics and role of these DNA binding proteins using WT and KO cells and expression constructs, and to explore in cells and embryos their effects on genomic imprinting. This research project uses the mouse as a model system and should enhance our understanding of genomic imprinting and its deregulation in congenital diseases and cancer.
The position is in the ‘Genomic Imprinting and Development’ group (head: Robert Feil), who are interested in recruiting a motivated candidate who is at an early stage after obtaining her/his Ph.D. degree, and has a strong background in molecular biology and experience in chromatin research and stem cell biology / embryology. Although not compulsory, skills in bioinformatics would ideally complement this profile.
The position is for 2 years and is expected to start the end of 2017/early 2018. The salary is provided by the University of Montpellier, in the context of the Laboratory of Excellence (Labex) EpiGenMed ( https://www.epigenmed.fr/ ).
Applicants should send their Curriculum Vitae, two references and a letter of motivation to Dr. Robert Feil, who can be contacted for informal inquiries as well.
Recent publications from the laboratory:
Llères D et al. (2017). Cell reports, 18, 1791-1803.
Auclair G et al. (2016). Genome Research, 26, 192-202.
Puget N et al. (2015). Mol. Cell. Biol. 35, 529-543.
Kota SK et al. (2014). Developmental Cell, 31, 19-33.
Girardot M et al. (2014). Nucleic Acids Res., 42, 235-248.
Kelsey G & Feil R (2013). Phil. Trans. R. Soc. B, 368, 20110336.
I am looking for an ambitious postdoc that is interested in studying spatio-temporal Rho GTPase during neuronal guidance (live cell FRET imaging, computer vision techniques, …). The position is funded for an initial period of two years.
The cellular dynamics lab (http://www.izb.unibe.ch/research/prof_dr_olivier_pertz/index_eng.html) studies spatio-temporal signaling networks that regulate cytoskeletal dynamics (during cell migration or neuronal differentiation), or the control of cell fate decisions. For that purpose, we utilize state of the art imaging techniques to visualize signaling activities in single living cells, microfluidics technology to precisely manipulate these cells, computer vision approaches for automated analysis of our imaging datasets, and mathematical modeling to extract meaningful
insights from our experiments.
The project deals with the identification of spatio-temporal Rho GTPase signaling network regulating neuronal growth cone motility and neurite outgrowth dynamics. The project will involve imaging spatio-temporal patterns of Rho GTPase activity using FRET probes in live neuronal growth cones, siRNA perturbations and automated image analysis. The goal of the project is to
formulate a model of spatio-temporal Rho GTPase signaling regulating cytoskeletal dynamics in neuronal motility. This position is funded by the Swiss National Foundation, and takes place in
collaboration with the lab of Alfredo Caceres at the National University of Cordoba, Argentina.
Please look at recent relevant publications:
A versatile toolkit to produce FRET-based biosensors to visualize signaling events in time and space. Science Signaling. 2013 Jul 23;6(285).
SrGAP2-Dependent Integration of Membrane Geometry and Slit-Robo-Repulsive Cues Regulates Fibroblast Contact Inhibition of Locomotion. Developmental Cell. 2015 Oct ;35(1):78-92.
Computer vision profiling of neurite outgrowth dynamics reveals spatiotemporal modularity of Rho GTPase signaling. J Cell Biol. 2016 Jan 4;212(1):91-111.
Candidates with a PhD Degree in Biology, Biochemistry, Bioengineering or a closely related field should apply. Experience with molecular biology, cell culture, live cell imaging and programing are
advantages, but are not an absolute requirement. The postdoc is expected to interact with mathematicians that will perform modeling/image analysis. Excellent spoken and written English
are required. Only short-listed candidates will be contacted.
We offer a vibrant and collegial research environment consisting of international students and PIs, and an outstanding research infrastructure, especially when it comes to live cell imaging. The
position is funded for two years. Competitive salaries are awarded according to regulations from the Swiss National Science Foundation.
Applications with a full CV, references and a cover letter with a short research statement should be
submitted by email to Olivier Pertz
« Destiny of mRNAs & genetic diseases »
A postdoctoral position is available in the Functional Genomics section of Institut de Biologie de l’ENS in Paris, France. The team investigates RNA-protein complexes that dictate the destiny of messenger RNAs, notably their quality control and their cellular localization in different cellular models including human cell lines and differentiating neural stem cells (https://www.ibens.ens.fr/spip.php?rubrique42). A particular emphasis is given onto RNA helicases that are molecular motors ensuring RNP complex dynamics. Multiple research approaches are combined, from biochemistry to single molecule biophysics, molecular and cellular biology as well as transcriptomics.
Contact: Hervé Le Hir, PhD E-mail: email@example.com
Institut de Biologie de l’ENS, Functional Genomics
CNRS UMR8197 – INSERM U1024
46, rue d’Ulm – 75230 Paris cedex 05 - France
Tel : 01 44 32 39 45
We are currently inviting applications from enthusiastic and independent post-doctoral candidates to participate in our
ANR LabEx-funded project (a fully funded 2-year postdoc position).
The research program centers on viruses of the flaviviridae family (Dengue, zika virus, HCV) and the activation of the innate immune response via the sensing of infected cells, as well as viral strategies for immune
CIRI, Center for Infectiology Research
INSERM U1111–CNRS UMR5308 – Université
Lyon 1– ENS Lyon, France http://ciri.inserm.fr/team/all-teams/
Please send one PDF file to Marlene Dreux firstname.lastname@example.org containing the following:
– cover letter (with short statement of the research interests)
– concise summary of previous research activities
– curriculum vitae including publication list and contact details for 2-3 referees
A post-doctoral fellowship The Institut du Cerveau et de la Moelle épinière (ICM), offers A post-‐doctoral fellowship (3 to 5 years expérience) in: « Stem Cell and Myelin Repair » CDD (m/f) Paris 13 Arr. The Institut du « Cerveau et de la Moelle épinière » is a private foundation, which objective is fundamental and clinical research of the nervous system. Reunited in one site, 600 researchers, ingenieurs et clinicians cover most of the disciplines in Neurology with the aim to accelerate discoveries in brain functioning, and developments of treatment for diseases such as: Alzheimer, Parkinson, Multiple Sclerosis, epilepsy, depression, paraplegia, tetraplegia, etc.
CV to send to : email@example.com (ou) or by postal mail to « Service recrutement, Poste « Stagiaire Post–‐doctoral : Cellules souches et Réparation de la Myéline » (m/f) : ICM –‐ Hôpital Pitié Salpêtrière 47 Boulevard de l’Hôpital –‐ 75013 Paris